Please assess the completion status of the following clinical trial:

Trial Title: Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 16 years of age~* Have a confirmed diagnosis of sickle cell anemia (HbSS) or sickle cell beta zero thalassemia~* Have evidence of persistent elevation of pulmonary artery systolic pressure on Doppler echocardiography (TR jet velocity of 2.5 to 2.9 m/s \[or estimated pulmonary artery systolic pressure above the upper limit of reference adjusted ranges and up to 45 mm Hg\]), but no evidence of moderate or severe diastolic dysfunction on tissue Doppler echocardiography. Mild PHT must be confirmed on repeat evaluation, at least 3 months later~* Have a serum creatinine =/\< 1.5 mg/dl~* Have serum transaminase values (ALT) \< 2 times upper limits of normal~* Have serum albumin =/\> 3.2 g/dl~* Have a platelet count =/\< 150,000 cu/mm~* Have normal baseline coagulation profile (PT/PTT)~* Patients on treatment with hydroxyurea should be on a stable dose for at least 6 months. Doses of hydroxyurea may only be adjusted during the course of the study for safety reasons.~* Be able to understand the requirements of the study and be willing to give informed consent.~* Women of childbearing age must be practicing (and will continue to practice for the course of the study) an adequate method of contraception.~Exclusion Criteria:~* Have a baseline hemoglobin \< 6.0 gm/dl~* Have congenital heart disease, valvular heart disease, and other identified cause of pulmonary hypertension (including pulmonary fibrosis) unrelated to SCD~* Have an elevated pulmonary capillary wedge pressure, as evidenced by E/Em \> 15 by pulsed wave and tissue Doppler imaging~* Have no measurable tricuspid regurgitant velocity on echocardiography~* Have a history of major gastrointestinal bleeding or a bleeding diathesis~* Have sickle cell complications such as recent vaso-occlusive crisis or acute chest syndrome, 4-weeks prior to commencing the study~* Have a history of clinically overt stroke(s) or seizures~* Have a brain magnetic resonance imaging/magnetic resonance angiography scan with evidence of Moya Moya within the preceding year~* Are pregnant or breastfeeding~* Are on chronic anticoagulant therapy~* Have a history of metastatic cancer~* Are chronically on therapy with aspirin or non-steroidal anti-inflammatory agents~* Are on a chronic transfusion program or have received a blood transfusion in the prior 8 weeks~* Have a positive urine toxicology screen for cocaine and amphetamines~* Have a history of alcohol abuse~* Are currently receiving treatment with epoprostenol (or similar prostacyclin analog), sildenafil (or similar phosphodiesterase 5 inhibitor), bosentan or arginine~* Have ingested any investigational drugs within the past 4 weeks.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Warfarin (Type: ACTIVE_COMPARATOR): Patients on the active treatment arm will be anticoagulated using the vitamin K antagonist, warfarin
- Placebo (Type: PLACEBO_COMPARATOR): matching active products

Based on this trial design, predict the completion outcome and termination type (if applicable).